NewAmsterdam Pharma NAMS
NASDAQ NAMS
$24.16 -0.16 (-0.66%)
At close: Oct 1, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2021 - 2026)

Updated

NewAmsterdam Pharma's Liabilities and Shareholders Equity came in at $704.45 million for Q2 2026, down 13.6% from $815.11 million a year earlier and down 3.8% from the prior quarter.

Analysis

NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

At the end of FY2025, NewAmsterdam Pharma's Liabilities and Shareholders Equity was $769.28 million, down 11.0% from FY2024.

  • Liabilities and Shareholders Equity carries a four-year compound annual growth rate of 81.6% (FY2021 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $864.62 million in FY2024 (+149.1%), $347.1 million in FY2023 (-38.0%), $560.27 million in FY2022 (+691.9%) and $70.75 million in FY2021.
  • The Q2 2026 figure represents the lowest quarterly Liabilities and Shareholders Equity since Q3 2024.
  • Year-over-year, Liabilities and Shareholders Equity has declined for three consecutive quarters, with growth averaging 49.0% over the last seven quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q4 2022 (growth of 693.0%), and the weakest in Q4 2023 (a decline of 36.0%).
  • Business Quant data shows NAMS's Liabilities and Shareholders Equity at $732.64 million (Q1 2026), $769.28 million (Q4 2025) and $786.43 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 NewAmsterdam Pharma 2.86 Bn 2.86 Bn - 704.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 704.45 Mn
Mar 31, 2026 732.64 Mn
Dec 31, 2025 769.28 Mn
Sep 30, 2025 786.43 Mn
Jun 30, 2025 815.11 Mn
Mar 31, 2025 818.41 Mn
Dec 31, 2024 864.62 Mn
Sep 30, 2024 439.19 Mn
Jun 30, 2024 446.69 Mn
Mar 31, 2024 488.46 Mn
Dec 31, 2023 347.10 Mn
Jun 30, 2023 512.99 Mn
Dec 31, 2022 542.35 Mn
Dec 31, 2021 68.39 Mn
API Access

NewAmsterdam Pharma Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NAMS&period=max&api_key=YOUR_API_KEY